Excellent Clinical Results for New Treatment of Bacterial Vaginosis
HELSINGBORG, Sweden, October 22, 2012 /PRNewswire/ –
The Swedish company Laccure AB has developed a breakthrough product for treatment and
prevention of bacterial vaginosis (BV) with a proven cure rate of 80 percent already after
one vaginal tablet. The product recently got CE marking as a Class II a medical device.
Addressing the unmet needs of the 300 million women suffering from BV infection, the new
treatment represents a considerable commercial potential in the OTC market.
Laccure’s novel, non-prescription vaginal tablet has been tested in randomized
controlled clinical multicenter studies including 126 women. The results show a cure rate
of 80 percent following a single administration of one (1) vaginal tablet. Along with a
good safety profile and by fully meeting women’s need for user-friendly comfort, this
represents a major improvement in the treatment of BV. Moreover, the use of this new
treatment might significantly reduce the need for antibiotics and consequently limit the
risk of antibiotic resistance. The product is based on a proprietary substance that
releases lactic acid over an extended period of time to decrease elevated vaginal pH.
“Showing such high cure rates already a week after single administration exceeded our
ambitious expectations for this product. The study results have been confirmed in two
independent studies which led to the successful CE marking, says Dr. Jeanette Robertsson,
CEO of Laccure AB.
“As there is a lack of effective and user-friendly treatment that is also effective in
preventing recurrent episodes of bacterial vaginosis, this product will truly fill an
unmet need in the market. Product launch in early 2013 is entirely possible if we can find
the right marketing partner”, says Dr. Lennart Bruce, Board Member of Laccure AB.
About Bacterial Vaginosis
Bacterial Vaginosis (BV) is the most common vaginal infection in women of childbearing
age. It is estimated that more than 300 million women worldwide are infected each year. BV
is caused by an imbalance in the naturally occurring bacterial flora of the vaginal mucosa
resulting in lack of vaginal acidity, discharge with a pronounced foul, fishy odor and
inhibition of the normal lactobacilli growth. Many women suffer from frequent recurrences.
Today, there is a lack of effective and safe products that are also user-friendly. Women
are often embarrassed having BV and quality of life is negatively affected.
Laccure was founded in 2007 and is a Swedish project company of the life-science incubator
P.U.L.S. AB. Initial product research was carried out at the University of Lund, Sweden,
and University of Gdansk, Poland. Further pharmaceutical development and GMP manufacturing
for clinical trials as well as preclinical and clinical studies have been performed in
collaboration with a number of contract development organisations. Laccure is certified by
For more information visit http://www.laccure.com and
SOURCE Laccure AB